Literature DB >> 14697335

HGF and ligation of alphavbeta5 integrin induce a novel, cancer cell-specific gene expression required for cell scattering.

Sonya Crouch1, Celee S Spidel, J Suzanne Lindsey.   

Abstract

Hepatocyte growth factor (HGF), a cytokine involved in tumorigenesis and most metastases, initiates cell migration by binding to the protooncogene c-Met receptor. In epithelial carcinoma cells, c-Met activation causes the breakdown of E-cadherin cell-cell contacts leading to cell spreading. While the breakdown of E-cadherin contacts is immediate, HGF-induced migration requires transcription. To test the hypothesis that this de novo mRNA synthesis includes cancer cell-specific transcripts, we performed subtraction hybridization to isolate HGF-induced transcripts from an endometrial epithelial carcinoma cell line, RL95-2 (RL95), known to migrate but not to proliferate with HGF treatment. One novel cDNA we call Mig-7 is induced by HGF in endometrial epithelial carcinoma cell lines RL95 and HEC-1A before migration ensues. Ovarian, oral squamous cell, and colon metastatic tumors but not normal tissues express Mig-7. HGF did not induce Mig-7 in normal primary endometrial epithelial cells. In addition, blocking antibodies to alphavbeta5 integrin inhibited HGF induction of Mig-7 in RL95 cells. Most importantly, Mig-7-specific antisense oligonucleotides inhibited scattering of RL95 cells in vitro. These results are the first to demonstrate that Mig-7 expression may be used as a cancer cell-specific target to inhibit cell scattering.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14697335     DOI: 10.1016/j.yexcr.2003.09.016

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  13 in total

Review 1.  Mig-7 linked to vasculogenic mimicry.

Authors:  Gavin P Robertson
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

2.  Matrix-coated transwell-cultured TM4 sertoli cell testosterone-regulated gene expression mimics in vivo expression.

Authors:  Brianna C Prante; Kiera L Garman; Brandon N Sims; J Suzanne Lindsey
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-09-23       Impact factor: 2.416

3.  T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways.

Authors:  Yukinori Endo; Yi Shen; Lamis Abou Youssef; Nishant Mohan; Wen Jin Wu
Journal:  MAbs       Date:  2018-09-11       Impact factor: 5.857

Review 4.  Integrins in cancer: biological implications and therapeutic opportunities.

Authors:  Jay S Desgrosellier; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

5.  Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy.

Authors:  Yue-Zu Fan; Wei Sun
Journal:  World J Gastrointest Surg       Date:  2010-04-27

6.  Overexpression of carcinoma and embryonic cytotrophoblast cell-specific Mig-7 induces invasion and vessel-like structure formation.

Authors:  Aaron P Petty; Kiera L Garman; Virginia D Winn; Celee M Spidel; J Suzanne Lindsey
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

7.  Targeting migration inducting gene-7 inhibits carcinoma cell invasion, early primary tumor growth, and stimulates monocyte oncolytic activity.

Authors:  Aaron P Petty; Stephen E Wright; Kathleen A Rewers-Felkins; Michelle A Yenderrozos; Beth A Vorderstrasse; J Suzanne Lindsey
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

8.  Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis.

Authors:  Lisa Mohamet; Kate Hawkins; Christopher M Ward
Journal:  J Oncol       Date:  2010-12-09       Impact factor: 4.375

9.  MIG-7 and phosphorylated prohibitin coordinately regulate lung cancer invasion/metastasis.

Authors:  Ming-Yi Ho; Chi-Ming Liang; Shu-Mei Liang
Journal:  Oncotarget       Date:  2015-01-01

10.  Recombinant viral capsid protein VP1 suppresses lung cancer metastasis by inhibiting COX-2/PGE2 and MIG-7.

Authors:  Ming-Yi Ho; Shao-Wen Hung; Chi-Ming Liang; Shu-Mei Liang
Journal:  Oncotarget       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.